Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer


Unattributed VC | Alive

Total Raised


Last Raised

$13.8M | 10 yrs ago

About Phosphate Therapeutics

Phosphate Therapeutics is an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals. The company is developing its PT20 drug, which is designed to treat hyperphosphataemia. Patients with late-stage renal disease suffer from systemic phosphate accumulation, hyperphosphataemia, which enhances the risk of vascular calcification, leading to increased morbidity and mortality. Low phosphate diets and regular dialysis sessions are unable to prevent gradual phosphate accumulation, therefore, oral phosphate binders are required to reduce blood phosphate levels. Current treatments are often limited by at least one of the following problems: limited therapeutic dosing range, low specificity, high pill loading, gastrointestinal side effects, calcium loading or significant toxicity concerns.

Phosphate Therapeutics Headquarter Location

Hollins Chambers Bridge Street

M3 3BA,

United Kingdom

Latest Phosphate Therapeutics News

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

May 7, 2015

Published on May 7, 2015 at 7:11 AM· No Comments Phosphate Therapeutics Limited ("Phosphate Therapeutics"), a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD). PT20, invented in the UK by leading Cambridge-based scientists and exclusively licensed by Phosphate Therapeutics, is a novel phosphate binder that is based on proprietary 'Interstitial Mineral Hydroxide' technology that uses adipate-doped iron oxide at the core of the product, thereby allowing PT20 to act as a very high capacity 'phosphate sponge'. This first pivotal study of PT20 in approximately 150 subjects with hyperphosphataemia related to DD-CKD, clearly met its primary endpoint (p<0.0001) demonstrating that PT20 successfully lowered serum phosphate levels compared to placebo, whilst all secondary analyses of the primary endpoint were also statistically significant (p<0.01). All of the study's PT20 dose groups showed a phosphate reduction at day 28 compared to baseline and this reduction was dose-related. PT20 was very well tolerated with less than 5% of the patients who received study medication withdrawing because of adverse events; and no Serious Adverse Events were considered related to study medication. The PEACH study (A Pharmacodynamic Evaluation of Adipate modified iron in subjects with Chronic kidney disease and Hyperphosphataemia) was a pivotal Phase 2b, multi-centre, placebo-controlled, randomised study of a wide range of doses of PT20 in dialysis dependent subjects with hyperphosphataemia. This study was conducted in more than 20 expert nephrology centres in the USA, with Dr Geoffrey Block as the Principal Investigator. Dr Block is a widely published and world-recognised clinical expert in kidney disease and mineral metabolism disorders and is Adjunct Professor of Medicine at University of Colorado, as well as Director of Clinical Research at Denver Nephrology. Related Stories

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Phosphate Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Phosphate Therapeutics is included in 2 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.



5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.